数字药丸市场
数字药丸市场：2026年市场规模约为62亿美元，2031年市场规模约为111.6亿美元；预测期复合年增长率为12.45%；当前最大市场为北美；增长最快的市场为亚太地区。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
数字药丸市场：2026年市场规模约为62亿美元，2031年市场规模约为111.6亿美元；预测期复合年增长率为12.45%；当前最大市场为北美；增长最快的市场为亚太地区。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 12.45% | 机构预测 |
| 市场规模 | 2026 | USD 6.2 billion | 机构预测 |
| 市场规模 | 2031 | USD 11.16 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| disease | infectious diseases | 2025 | 56.760% |
| end_user | hospitals | 2025 | 53.240% |
| geography | North America | 2025 | 42.450% |
| indication | medication adherence | 2025 | 34.550% |
| product_type | capsules | 2025 | 61.400% |
关键结论
- disease 维度中，infectious diseases 在 2025 年的公开份额为 56.76%。
- end_user 维度中，hospitals 在 2025 年的公开份额为 53.24%。
- geography 维度中，North America 在 2025 年的公开份额为 42.45%。
- indication 维度中，medication adherence 在 2025 年的公开份额为 34.55%。
- product_type 维度中，capsules 在 2025 年的公开份额为 61.4%。
主要参与者
- Medtronic plc
- Olympus Corporation
- Otsuka Pharmaceutical Co., Ltd.
- CapsoVision, Inc.
- IntroMedic Co., Ltd.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Objective medication-adherence measurement | +2.800% | Global, with demand concentrated in North America and Europe | Short term (≤ 2 years) |
| Decentralized and hybrid clinical trials | +2.000% | Global, with early gains in North America and the EU | Medium term (2-4 years) |
| Regulatory precedent for ingestible event markers | +1.800% | North America and the EU, with spillover to the Asia-Pacific | Short term (≤ 2 years) |
| Remote monitoring in chronic therapy | +2.000% | Global, with primary relevance in North America and the Asia-Pacific | Medium term (2-4 years) |
| Pharmacy and care-team integration of dose-level data | +1.300% | North America and the EU | Long term (≥ 4 years) |
| Reusable reader and wearable form-factor innovation | +1.100% | Global | Medium term (2-4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| High total cost of sensor-enabled therapy | -1.500% | Global, with the greatest relevance in lower-income and emerging markets | Medium term (2-4 years) |
| Limited reimbursement and unproven outcomes at scale | -1.200% | North America and the EU, with spillover to the Asia-Pacific | Short term (≤ 2 years) |
| Dose-detection failure and data-latency risk | -0.800% | Global | Short term (≤ 2 years) |
| Patient consent, privacy, and workflow friction | -0.500% | Global, with particular relevance in GDPR-regulated EU markets | Medium term (2-4 years) |
报告关注的关键问题
What is driving growth in digital pills?
Objective medication records, decentralized research, regulatory clarity, and remote chronic-care use support adoption. The Digital pills market is forecast to grow at a 12.45% CAGR from 2026 to 2031.
Which digital pill product type has the largest share?
Capsules held 61.40% of revenue in 2025. Their position is supported by capsule endoscopy and the ability to add sensors around existing formulations.
What is the fastest-growing application for digital pills?
Patient monitoring is forecast to grow at a 14.51% CAGR through 2031. The application includes gastrointestinal monitoring as well as ingestion-related information.
Which end users are adopting digital pill systems most quickly?
Clinics are forecast to grow at a 14.55% CAGR through 2031. Their model can fit ambulatory chronic-care programs when pharmacy and care-team processes are in place.
Which region is growing fastest for digital pills?
Asia-Pacific is forecast to grow at a 15.20% CAGR through 2031. Regulatory modernization and expanding diagnostic infrastructure support its outlook.
What limits wider use of ingestible sensor systems?
Added treatment costs, uneven reimbursement, data reliability concerns, consent requirements, and workflow demands can limit adoption.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence